STOCK TITAN

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences clinical trial

Innovent Biologics (IVBIY) announces the presentation of preclinical data for multiple novel cancer therapeutics at the 2025 AACR Annual Meeting in Chicago from April 25-30. The presentations include data on several groundbreaking molecules:

- IAR037: A novel CD40/PD-L1 bispecific antibody for advanced solid tumors
- IBI3010: A FRα targeting biparatopic antibody-drug conjugate
- IBI3019: A first-in-class EGFR/CDH17/CD16A tri-specific antibody for colorectal cancer
- IBI3026: A novel anti-PD-1/IL-12 fusion protein
- IBI3014: A TROP2xPD-L1 bi-specific ADC

The company will also present findings on combination therapies involving olverembatinib with lisaftoclax for leukemia treatment. These presentations showcase Innovent's expanding technological capabilities in developing first-in-class bispecific antibodies, multi-specific antibodies, and ADCs for oncology applications.

Innovent Biologics (IVBIY) annuncia la presentazione di dati preclinici per molteplici nuovi terapeutici contro il cancro al 2025 AACR Annual Meeting a Chicago dal 25 al 30 aprile. Le presentazioni includono dati su diverse molecole innovative:

- IAR037: Un nuovo anticorpo bispecifico CD40/PD-L1 per tumori solidi avanzati
- IBI3010: Un coniugato anticorpo-farmaco biparatopico mirato a FRα
- IBI3019: Un anticorpo tri-specifico EGFR/CDH17/CD16A per il cancro colorettale
- IBI3026: Una nuova proteina di fusione anti-PD-1/IL-12
- IBI3014: Un ADC bi-specifico TROP2xPD-L1

La società presenterà anche risultati su terapie combinate che coinvolgono olverembatinib con lisaftoclax per il trattamento della leucemia. Queste presentazioni evidenziano le capacità tecnologiche in espansione di Innovent nello sviluppo di anticorpi bispecifici di prima classe, anticorpi multi-specifici e ADC per applicazioni oncologiche.

Innovent Biologics (IVBIY) anuncia la presentación de datos preclínicos para múltiples nuevos terapéuticos contra el cáncer en el 2025 AACR Annual Meeting en Chicago del 25 al 30 de abril. Las presentaciones incluyen datos sobre varias moléculas innovadoras:

- IAR037: Un nuevo anticuerpo bispecífico CD40/PD-L1 para tumores sólidos avanzados
- IBI3010: Un conjugado anticuerpo-fármaco biparatópico dirigido a FRα
- IBI3019: Un anticuerpo tri-específico de primera clase EGFR/CDH17/CD16A para el cáncer colorrectal
- IBI3026: Una nueva proteína de fusión anti-PD-1/IL-12
- IBI3014: Un ADC bi-específico TROP2xPD-L1

La empresa también presentará hallazgos sobre terapias combinadas que involucran olverembatinib con lisaftoclax para el tratamiento de la leucemia. Estas presentaciones destacan las capacidades tecnológicas en expansión de Innovent en el desarrollo de anticuerpos bispecíficos de primera clase, anticuerpos multi-específicos y ADC para aplicaciones oncológicas.

Innovent Biologics (IVBIY)는 2025 AACR 연례 회의에서 시카고에서 4월 25일부터 30일까지 여러 새로운 암 치료제에 대한 전임상 데이터를 발표한다고 발표했습니다. 발표 내용에는 여러 혁신적인 분자에 대한 데이터가 포함되어 있습니다:

- IAR037: 고급 고형 종양을 위한 새로운 CD40/PD-L1 이중 특이성 항체
- IBI3010: FRα를 표적으로 하는 이중 특이성 항체-약물 접합체
- IBI3019: 대장암을 위한 최초의 EGFR/CDH17/CD16A 삼중 특이성 항체
- IBI3026: 새로운 항-PD-1/IL-12 융합 단백질
- IBI3014: TROP2xPD-L1 이중 특이성 ADC

회사는 또한 백혈병 치료를 위한 olverembatinib과 lisaftoclax의 병용 요법에 대한 결과를 발표할 예정입니다. 이러한 발표는 혁신적인 이중 특이성 항체, 다중 특이성 항체 및 ADC 개발에서 Innovent의 기술적 역량이 확장되고 있음을 보여줍니다.

Innovent Biologics (IVBIY) annonce la présentation de données précliniques pour plusieurs nouveaux thérapeutiques contre le cancer lors de la 2025 AACR Annual Meeting à Chicago, du 25 au 30 avril. Les présentations incluent des données sur plusieurs molécules révolutionnaires :

- IAR037 : Un nouvel anticorps bispécifique CD40/PD-L1 pour les tumeurs solides avancées
- IBI3010 : Un conjugé anticorps-médicament biparatopique ciblant FRα
- IBI3019 : Un anticorps tri-spécifique de première classe EGFR/CDH17/CD16A pour le cancer colorectal
- IBI3026 : Une nouvelle protéine de fusion anti-PD-1/IL-12
- IBI3014 : Un ADC bispécifique TROP2xPD-L1

L'entreprise présentera également des résultats sur des thérapies combinées impliquant l'olverembatinib avec le lisaftoclax pour le traitement de la leucémie. Ces présentations mettent en avant les capacités technologiques croissantes d'Innovent dans le développement d'anticorps bispécifiques de première classe, d'anticorps multi-spécifiques et d'ADCs pour des applications oncologiques.

Innovent Biologics (IVBIY) gibt die Präsentation von präklinischen Daten zu mehreren neuartigen Krebstherapeutika auf dem 2025 AACR Annual Meeting in Chicago vom 25. bis 30. April bekannt. Die Präsentationen umfassen Daten zu mehreren bahnbrechenden Molekülen:

- IAR037: Ein neuartiger CD40/PD-L1 bispezifischer Antikörper für fortgeschrittene solide Tumoren
- IBI3010: Ein FRα-zielgerichteter biparatopischer Antikörper-Wirkstoff-Konjugat
- IBI3019: Ein erstklassiger EGFR/CDH17/CD16A tri-spezifischer Antikörper für kolorektalen Krebs
- IBI3026: Ein neuartiges anti-PD-1/IL-12 Fusionsprotein
- IBI3014: Ein TROP2xPD-L1 bispezifisches ADC

Das Unternehmen wird auch Ergebnisse zu Kombinationstherapien vorstellen, die Olverembatinib mit Lisaftoclax zur Behandlung von Leukämie kombinieren. Diese Präsentationen zeigen die wachsenden technologischen Fähigkeiten von Innovent bei der Entwicklung von erstklassigen bispezifischen Antikörpern, multispezifischen Antikörpern und ADCs für onkologische Anwendungen.

Positive
  • Development of multiple first-in-class cancer therapeutics
  • Diverse pipeline of novel bispecific antibodies and ADCs
  • Promising preclinical efficacy data across multiple cancer types
  • Strategic partnership with Ascentage Pharma for olverembatinib commercialization
Negative
  • All treatments still in preclinical stage, requiring extensive clinical trials
  • No immediate revenue impact as products are years from potential commercialization

SAN FRANCISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will take place from April 25 to April 30, 2025, in Chicago, Illinois.

Late-Breaking Research: Immunology 2

Topic: Preclinical Data of IAR037, A Novel CD40/PD-L1 Bispecific Antibody for the Treatment of Advanced Solid Tumors Resistant to Immune Checkpoint Inhibitors
Abstract Number: LB139
Presentation TimeMonday Apr 28, 2025 9:00 AM - 12:00 PM
Location: Poster Section 52

Late-Breaking Research: Clinical Research 1

Topic: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
Abstract Number: LB222
Presentation TimeMonday Apr 28, 2025 2:00 PM - 5:00 PM
Location: Poster Section 53

Poster Session: Experimental and Molecular Therapeutics - New and Emerging Cancer Drug Targets

Topic: IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies
Abstract Number: 4249
Presentation Time: Tuesday Apr 29, 2025 9:00 AM - 12:00 PM
Location: Poster Section 17
Poster Board Number: 6

Poster Session: Experimental and Molecular Therapeutics - Therapeutic Approaches to Attack the Tumor Microenvironment

Topic: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment
Abstract Number: 3118
Presentation Time: Monday Apr 28, 2025 2:00 PM - 5:00 PM
Location: Poster Section 24
Poster Board Number: 2

Poster Session: Experimental and Molecular Therapeutics - Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies

Topic: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
Abstract Number: 344
Presentation Time: Sunday Apr 27, 2025 2:00 PM - 5:00 PM
Location: Poster Section 16
Poster Board Number: 11

Poster Session: Experimental and Molecular Therapeutics - Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies

Topic: Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers
Abstract Number: 345
Presentation Time: Sunday Apr 27, 2025 2:00 PM - 5:00 PM
Location: Poster Section 16
Poster Board Number: 12

Poster Session: Immunology - T Cell Engagers

Topic: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy
Abstract Number: 3510
Presentation Time: Monday Apr 28, 2025 2:00 PM - 5:00 PM
Location: Poster Section 38
Poster Board Number: 18

Poster Session: Immunology - Modulation of Tumor Microenvironment: Modulation of Lymphocyte Influx

Topic: A PD1-IFNα fusion protein, composed of an attenuated IFNα fused to a clinically validated PD1 mAb, induced PD1-dependent IFNα signaling and demonstrated superior anti-tumor efficacy
Abstract Number: 4881
Presentation Time: Tuesday Apr 29, 2025 9:00 AM - 12:00 PM
Location: Poster Section 40
Poster Board Number: 9

Poster Session: Experimental and Molecular Therapeutics - Novel Antitumor Agents 3

Topic: Olverembatinib* (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML)
Abstract Number: 5652
Presentation Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM

Poster Session: Experimental and Molecular Therapeutics - Novel Antitumor Agents 3

Topic: Effects of olverembatinib* (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell acute lymphoblastic leukemia (T ALL)
Abstract Number: 5648
Presentation Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM

* In July 2021, Innovent and Ascentage Pharma (6855.HK) reached the agreement regarding the joint development and commercialization of olverembatinib in China.

Dr. Kaijie He, Vice President of Innovent, stated: "With the expansion and enhancement of Innovent Academy's technology platforms, our global R&D efforts are taking shape and accelerating global competitiveness, enabling the efficient generation of novel molecules with global potential. We are proud to showcase a batch of preclinical research findings at this year's AACR Annual Meeting, including multiple globally first-in-class bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs). These breakthroughs not only demonstrate our growing scientific capabilities but also reaffirm our commitment to delivering transformative therapeutic options for patients worldwide. Moving forward, we remain focused on innovation—optimizing precision targets and exploring novel mechanisms—to provide revolutionary solutions for some of the world's most challenging diseases and enable more patients to benefit from the rapid advancements in cutting-edge science." 

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 16 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

Cision View original content:https://www.prnewswire.com/news-releases/innovent-to-present-preclinical-data-of-multiple-novel-molecules-at-the-2025-aacr-annual-meeting-302412693.html

SOURCE Innovent Biologics

FAQ

What new cancer treatments will IVBIY present at AACR 2025?

IVBIY will present preclinical data on multiple novel therapies including IAR037 for solid tumors, IBI3010 for FRα expressing tumors, IBI3019 for colorectal cancer, IBI3026 (PD-1/IL-12 fusion), and IBI3014 (TROP2xPD-L1 ADC).

When and where is IVBIY presenting at AACR 2025?

IVBIY will present at the AACR Annual Meeting in Chicago, Illinois from April 25-30, 2025, with multiple poster sessions scheduled between April 27-29.

What is the significance of IVBIY's IBI3019 treatment?

IBI3019 is a first-in-class EGFR/CDH17/CD16A tri-specific antibody that has demonstrated potent efficacy against colorectal cancer with an excellent safety profile in preclinical studies.

What are the leukemia treatments IVBIY is developing?

IVBIY is studying combinations of olverembatinib with lisaftoclax for both acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).
Innovent Biologi

OTC:IVBIY

IVBIY Rankings

IVBIY Latest News

IVBIY Stock Data

7.97B
91.64M
Biotechnology
Healthcare
Link
China
Suzhou